NL-OMON43094已完成不适用
Immune modulating effects and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with a history of (pre) malignant cervical lesions. - Vvax001 cancer vaccine in (pre) malignant cervical lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with a history of cervical intraepithelial neoplasia (CIN) II and III and patients with a history of cervical cancer, both minimally 12 weeks after completion of treatment.
排除标准
- •- Prior treatment with immunotherapeutic agents against HPV
- •- History of an autoimmune disease or other systemic intercurrent disease that might affect the immunocompetence of the patient, or current or prior use ( 4 weeks before start of the study) of high dose immunosuppressive therapy.
- •- History of a second malignancy except curatively treated low-stage tumors with a histology that can be differentiated from the cervical cancer type
- •- Participation in a study with another investigational drug within 30 days prior to the enrolment in this study
- •- Any condition that in the opinion of the investigator could interfere with the conduct of the study
- •- Pregnancy
研究者
相似试验
已完成
1 期
Vvax001 Cancer Vaccine in (Pre) Malignant Cervical LesionsCIN 2/3Cervical CancerNCT03141463University Medical Center Groningen12
尚未招募
1 期
CENTAURO-6 StudyLiver NeoplasmsCarcinoma, HepatocellularDigestive System NeoplasmsLiver DiseasesDigestive System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialHepatocellular carcinomaRPCEC00000237Center for Genetic Engineering and Biotechnology (CIGB), in Havana.20
进行中（未招募）
不适用
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster DoseHepatitis AEUCTR2015-005191-18-Outside-EU/EEASanofi Pasteur SA720
进行中（未招募）
1 期
This trial compares BI 695501 and Humira® in patients with a long-term disease that causes red, scaly patches on the skin (plaque psoriasis). The trial looks at the way the body takes up the drugs and how effective and safe they are.moderate to severe chronic plaque psoriasisMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858EUCTR2016-002254-20-LVBoehringer Ingelheim International GmbH240
进行中（未招募）
1 期
The VOLTAIRE-X trial looks at the effect of switching between Humira®and BI 695501 in patients with plaque psoriasisEUCTR2016-002254-20-PLBoehringer Ingelheim International GmbH259